William John Scheessele - 08 Dec 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: Chief Commercial Officer
Signature: /s/ William John Scheessele by Dale A. Sander as Attorney-in-Fact
Issuer symbol: HUMA
Transactions as of: 08 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 12 Dec 2022, 15:15:15 UTC
Previous filing: 25 May 2022
Next filing: 15 Dec 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award	$0	+136,000		$0.000000	136,000	08 Dec 2022	Common Stock	136,000	$3.07	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.